Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05031026
PHASE4

Dexmedetomidine to Prevent Hepatic Ischemia-reperfusion Injury-induced Glycocalyx Degradation and Early Allograft Dysfunction in Liver Transplantation

Sponsor: Assiut University

View on ClinicalTrials.gov

Summary

the aim of the study is to approve the hypothesis that dexmedetomidine can protect against glycocalyx degradation induced by hepatic ischemia-reperfusion injury and hence can reduce the subsequent complications as early allograft dysfunction, other organ dysfunction and hemodynamic instability

Official title: Dexmedetomidine Infusion to Prevent Hepatic Ischemia-reperfusion Injury-induced Glycocalyx Degradation and Early Allograft Dysfunction in the Sitting of Adult Living Donor Liver Transplantation

Key Details

Gender

All

Age Range

18 Years - 60 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2022-03-15

Completion Date

2026-02-15

Last Updated

2025-10-02

Healthy Volunteers

No

Interventions

DRUG

Dexmedetomidine

dexmedetomidine infusion rule in prevention of IRI

DRUG

Normal Saline

normal saline infusion as a placebo

Locations (1)

Assiut University

Asyut, Egypt